NCT04138875 2022-06-23
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
Yale University
Phase 2 Withdrawn
Clinical Trials
8 trialsNCT01332617 2017-12-29
Phase II Study of Simvastatin for Relapsed/Refractory Myeloma
University of Louisville
Phase 2 Withdrawn
NCT02623920 2017-05-19
S-BR
University of Arizona
Phase 2 Withdrawn
NCT01423539 2016-11-02
NAVIGATE
Genentech, Inc.
Phase 2 Withdrawn
NCT00939328 2015-03-06
S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT01649622 2012-11-08
Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00758693 2012-01-11
Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)
University of Kentucky
Phase 2 Withdrawn
NCT01131247 2011-07-20
PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab
Nevada Cancer Institute
Phase 2 Withdrawn